AURKB and neoplasm: In this work, the authors identify aurora kinase B (AURKB) as a critical therapeutic target for MCC, supported by tumour shrinkage and increased survival when using the AURKB inhibitor AZD2811 nanoparticle formulation in MCC preclinical models.